Neil Woodford is to meet the chief executive of Pfizer to discuss its bid for AstraZeneca.
According to Sky News, the star fund manager will sit down with Ian Read, the US giant’s boss, to talk through his concerns about the deal.
AstraZeneca rejected an improved offer of £63 billion, saying the amount ‘significantly undervalued AstraZeneca and its prospects’.
The stock is expected to be a key component of the newly launched Woodford Investment Management’s Income fund, which comes to market next month.
It is set to be another busy week for Read who today goes before MPs on the Business, Innovation and Skills Select Committee to discuss his plans for the combined business, should a deal go through. A number of politicians have raised concerns about the potential loss of jobs following a merger.
He said: 'While approaching the subject as a layman, the basic tenet of the research is that cancer can be transformed from a terminal illness to a chronic disease through immunotherapy.
‘We have purchased shares in AstraZeneca in the last six months; their predicament of significant revenue-earning patent expiries over the next few years has been heavily discounted by the stock market.
‘However, behind the other three companies, Astra’s portfolio of compounds is notable due to their expertise, with existing drugs across a wide spread of clinical outcomes. Given that many immunotherapies will incorporate other drugs in "combination therapies", AstraZeneca will have the option to commercialise a great deal of in-house compounds to late stage trials.'